Fundraising Fox
/Companies
Sign in

Genocea Biosciences

Cambridge, US · Delaware corporation · 8 known investors

Find your way into Genocea Biosciences

Sign up to see every warm intro you have to Genocea Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Genocea Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.

Biotech

Founders & leadership

NS
Narinder SinghExecutive
DM
Derek MeisnerGeneral Counsel2018–2019Derek Meisner is an executive officer at Genocea Biosciences, a company that uses T-cell antigen discovery to develop vaccines for oncology and infectious disease. He previously worked as a partner at an international law firm and served as Branch Chief at the U.S. Securities and Exchange Commission.
MA
Michael AlfieriExecutive
JF
Jessica FlechtnerExecutive
GA
Girish AakaluExecutive
TD
Thomas DavisExecutive
WC
William ClarkExecutive

Board

KBKatrine Bosley
Katrine BosleyBoard directorVenture Partner at Advent Life Sciences
ABAli Behbahani
Ali BehbahaniBoard directorPartner, Co-Head of Healthcare at New Enterprise Associates (NEA)
RC
Ronald CooperBoard director
MH
Michael HigginsBoard director
GS
George SiberBoard director

Investors · 8

Lux Capitallisted by Lux CapitalNew York · $100K – $100M

How we know: Lux Capital's portfolio page · Not right? Tell us

MC Healthcare Ventureslisted by MC Healthcare VenturesCambridge

How we know: MC Healthcare Ventures's portfolio page · Not right? Tell us

Advent Life SciencesinferredLondonvia Katrine Bosley · board

How we know: board seat on SEC Form D · Not right? Tell us

AlexandriareportedPasadena

How we know: funding news · Not right? Tell us

Auriga PartnersreportedParis · $540K – $5.4M

How we know: funding news · Not right? Tell us

Bill & Melinda Gates FoundationreportedSeattle

How we know: funding news · Not right? Tell us

New Enterprise Associates (NEA)inferredMenlo Park · $200K – $40Mvia Ali Behbahani · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$87.6M disclosed across 2 rounds · 2019–2020

▶$75.5MraisedAug 2020 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JESSICA FLECHTNERExecutive Officer
  • THOMAS DAVISExecutive Officer
  • KATRINE BOSLEYDirector
  • MICHAEL HIGGINSDirector
  • ALI BEHBAHANIDirector
  • GEORGE SIBERDirector
  • GIRISH AAKALUExecutive Officer
  • DIANTHA DUVALLExecutive Officer
  • GISELA SCHWABDirector
  • KENNETH BATEDirector
  • WILLIAM CLARKExecutive Officer
  • HOWARD MAYERDirector
  • RONALD COOPERDirector
Offering amount
$79.9M
Amount sold
$75.5M
Sales commissions
$4.8M
Placement agents
STIFEL, NICOLAUS & COMPANY, INCORPORATED
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.1MraisedFeb 2019 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Narinder SinghExecutive Officer
  • Derek MeisnerExecutive Officer
  • Michael AlfieriExecutive Officer
  • Katrine BosleyDirector
  • Jessica FlechtnerExecutive Officer
  • Ali BehbahaniDirector
  • Girish AakaluExecutive Officer
  • Ronald CooperDirector
  • Michael HigginsDirector
  • Thomas DavisExecutive Officer
  • George SiberDirector
  • William ClarkExecutive Officer
  • Kenneth BateDirector
  • Pamela CarrollExecutive Officer
  • Howard MayerDirector
Offering amount
$15M
Amount sold
$12.1M
Sales commissions
$750K
First sale
Feb 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Genocea Biosciences went on to found or lead other companies.

Kevin BittermanBoard of DirectorsFounded Editas MedicineDavid SinclairCo-Founder and Scientific AdvisorFounded Life Biosciences

Frequently asked questions

What does Genocea Biosciences do?
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
Who are Genocea Biosciences's investors?
Genocea Biosciences's investors include Cycad Group LLC, Lux Capital, MC Healthcare Ventures, Advent Life Sciences, Alexandria, Auriga Partners, Bill & Melinda Gates Foundation, New Enterprise Associates (NEA).
How much funding has Genocea Biosciences raised?
Genocea Biosciences has disclosed $87.6M raised across 2 rounds.
Where is Genocea Biosciences headquartered?
Genocea Biosciences is headquartered in Cambridge, US.